☰

David Y. Takeda, Ph.D. - Publications

Affiliations: 
2005 Harvard University, Cambridge, MA, United States 
Area:
Cell Biology, Biochemistry, Molecular Biology
Tree Info Similar researchers PubMed Report error

17/28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, Gusev A, Korthauer KD, Severson TM, Ha G, Viswanathan SR, Seo JH, Nguyen HM, Zhang B, Pasaniuc B, et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nature Genetics. PMID 32690948 DOI: 10.1038/S41588-020-0664-8  0.332
2018 Bellmunt J, Lalani AA, Jacobus S, Wankowicz SA, Polacek L, Takeda DY, Harshman LC, Wagle N, Moreno I, Lundgren K, Bossé D, Van Allen EM, Choueiri TK, Rosenberg JE. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. British Journal of Cancer. PMID 30220708 DOI: 10.1038/S41416-018-0261-0  0.324
2018 Sandoval GJ, Pulice JL, Pakula H, Schenone M, Takeda DY, Pop M, Boulay G, Williamson KE, McBride MJ, Pan J, St Pierre R, Hartman E, Garraway LA, Carr SA, Rivera MN, et al. Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis. Molecular Cell. PMID 30078722 DOI: 10.1016/J.Molcel.2018.06.040  0.384
2018 Takeda DY, Spisák S, Seo JH, Bell C, O'Connor E, Korthauer K, Ribli D, Csabai I, Solymosi N, Szállási Z, Stillman DR, Cejas P, Qiu X, Long HW, Tisza V, et al. A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. PMID 29909987 DOI: 10.1016/J.Cell.2018.05.037  0.345
2016 Sandoval GJ, Pulice JL, Takeda DY, Schenone MA, Pop M, Boulay G, Rivera MN, Ronco L, Hahn WC, Kadoch C. Abstract 882: TMPRSS2-ERG drives global mistargeting of mammalian SWI/SNF (BAF) complexes in prostate cancer Cancer Research. 76: 882-882. DOI: 10.1158/1538-7445.Am2016-882  0.399
2016 Dobi A, Petrovics G, Li H, Tan S, Stümpel T, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, ... ... Takeda D, et al. Abstract 140: LSAMP gene deletion is associated with rapid disease progression in prostate cancer of African American men Cancer Research. 76: 140-140. DOI: 10.1158/1538-7445.Am2016-140  0.356
2016 Tan S, Petrovics G, Li H, Stümpel T, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, ... ... Takeda D, et al. MP66-05 A NOVEL DELETION OF THE LSAMP GENE LOCUS ASSOCIATES WITH RAPID PROGRESSION OF PROSTATE CANCER AMONG AFRICAN AMERICAN MEN Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.1279  0.317
2015 Petrovics G, Li H, Stümpel T, Tan SH, Young D, Katta S, Li Q, Ying K, Klocke B, Ravindranath L, Kohaar I, Chen Y, Ribli D, Grote K, Zou H, ... ... Takeda D, et al. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. Ebiomedicine. 2: 1957-64. PMID 26844274 DOI: 10.1016/J.Ebiom.2015.10.028  0.334
2015 Pomerantz MM, Li F, Takeda DY, Lenci R, Chonkar A, Chabot M, Cejas P, Vazquez F, Cook J, Shivdasani RA, Bowden M, Lis R, Hahn WC, Kantoff PW, Brown M, et al. The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis. Nature Genetics. PMID 26457646 DOI: 10.1038/Ng.3419  0.356
2015 Miyahira AK, Kissick HT, Bishop JL, Takeda DY, Barbieri CE, Simons JW, Pienta KJ, Soule HR. Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. The Prostate. 75: 337-47. PMID 25358693 DOI: 10.1002/Pros.22920  0.317
2012 Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, et al. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 109: 11252-7. PMID 22730461 DOI: 10.1073/Pnas.1200853109  0.348
2005 Takeda DY, Shibata Y, Parvin JD, Dutta A. Recruitment of ORC or CDC6 to DNA is sufficient to create an artificial origin of replication in mammalian cells. Genes & Development. 19: 2827-36. PMID 16322558 DOI: 10.1101/Gad.1369805  0.51
2005 Takeda DY, Parvin JD, Dutta A. Degradation of Cdt1 during S phase is Skp2-independent and is required for efficient progression of mammalian cells through S phase. The Journal of Biological Chemistry. 280: 23416-23. PMID 15855168 DOI: 10.1074/Jbc.M501208200  0.517
2005 Takeda DY, Dutta A. DNA replication and progression through S phase. Oncogene. 24: 2827-43. PMID 15838518 DOI: 10.1038/Sj.Onc.1208616  0.504
2004 Saxena S, Yuan P, Dhar SK, Senga T, Takeda D, Robinson H, Kornbluth S, Swaminathan K, Dutta A. A dimerized coiled-coil domain and an adjoining part of geminin interact with two sites on Cdt1 for replication inhibition. Molecular Cell. 15: 245-58. PMID 15260975 DOI: 10.1016/J.Molcel.2004.06.045  0.495
2001 Wohlschlegel JA, Dwyer BT, Takeda DY, Dutta A. Mutational analysis of the Cy motif from p21 reveals sequence degeneracy and specificity for different cyclin-dependent kinases. Molecular and Cellular Biology. 21: 4868-74. PMID 11438644 DOI: 10.1128/Mcb.21.15.4868-4874.2001  0.59
2001 Takeda DY, Wohlschlegel JA, Dutta A. A bipartite substrate recognition motif for cyclin-dependent kinases. The Journal of Biological Chemistry. 276: 1993-7. PMID 11067844 DOI: 10.1074/Jbc.M005719200  0.568
Low-probability matches (unlikely to be authored by this person)
2018 Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, Howard TP, Takeda DY, Ly SH, Kim E, Gannon HS, Hurhula B, Sharpe T, Goodale A, Fritchman B, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nature Genetics. PMID 30224644 DOI: 10.1038/S41588-018-0204-Y  0.292
2016 Bellmunt J, Mullane S, Jacobus S, Polacek L, Takeda D, Harshman L, Choueiri T, Wagle N, Van Allen E, Kantoff P, Rosenberg J. Everolimus / pazopanib (E/P) benefits genomically selected patients (pts) with metastatic urothelial carcinoma (mUC) Annals of Oncology. 27: vi271. DOI: 10.1093/Annonc/Mdw373.13  0.283
2021 Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, et al. Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer. Nature Communications. 12: 1979. PMID 33785741 DOI: 10.1038/s41467-021-22139-7  0.267
2022 Tang S, Sethunath V, Metaferia NY, Nogueira MF, Gallant DS, Garner ER, Lairson LA, Penney CM, Li J, Gelbard MK, Alaiwi SA, Seo JH, Hwang JH, Strathdee CA, Baca SC, ... ... Takeda DY, et al. A genome-scale CRISPR screen reveals PRMT1 as a critical regulator of androgen receptor signaling in prostate cancer. Cell Reports. 38: 110417. PMID 35196489 DOI: 10.1016/j.celrep.2022.110417  0.247
2022 Stover EH, Oh C, Keskula P, Choudhury AD, Tseng YY, Adalsteinsson VA, Lohr JG, Thorner AR, Ducar M, Kryukov GV, Ha G, Rosenberg M, Freeman SS, Zhang Z, Wu X, ... ... Takeda DY, et al. Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples. The Prostate. PMID 35084050 DOI: 10.1002/pros.24305  0.239
2022 Baca SC, Singler C, Zacharia S, Seo JH, Morova T, Hach F, Ding Y, Schwarz T, Huang CF, Anderson J, Fay AP, Kalita C, Groha S, Pomerantz MM, Wang V, ... ... Takeda DY, et al. Genetic determinants of chromatin reveal prostate cancer risk mediated by context-dependent gene regulation. Nature Genetics. PMID 36071171 DOI: 10.1038/s41588-022-01168-y  0.238
2017 Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK, Lahr DL, Hirschman JE, Liu Z, Donahue M, Julian B, ... ... Takeda DY, et al. A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell. 171: 1437-1452.e17. PMID 29195078 DOI: 10.1016/J.Cell.2017.10.049  0.236
2022 Takeda DY, Sowalsky AG. Unpacking circulating tumor DNA lends insight into prostate cancer biology and the clonal dynamics of metastasis. Cancer Cell. 40: 1086-1088. PMID 36179684 DOI: 10.1016/j.ccell.2022.09.002  0.223
2015 Zhou CW, Mullane SA, Werner L, Taplin M, Fay AP, Choueiri TK, Takeda DY, Bowden M, Bellmunt J. Role of miR-21, miR372, and E2F1 as biomarkers predicting outcome in cisplatin-treated bladder cancer patients. Journal of Clinical Oncology. 33: 4530-4530. DOI: 10.1200/Jco.2015.33.15_Suppl.4530  0.217
2016 Bellmunt J, Zhou CW, Mullane SA, Werner L, Taplin ME, Fay AP, Choueiri TK, Orsola A, Takeda DY, Hahn WC, Kim J, Sonpavde G, Bowden M. Association of tumour microRNA profiling with outcomes in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy. British Journal of Cancer. 115: 12-19. PMID 27351382 DOI: 10.1038/Bjc.2016.146  0.216
2000 Nishiwaki H, Nakagawa Y, Takeda DY, Okazawa A, Akamatsu M, Miyagawa H, Ueno T, Nishimura K. Binding activity of substituted benzyl derivatives of chloronicotinyl insecticides to housefly-head membranes, and its relationship to insecticidal activity against the housefly Musca domestica Pest Management Science. 56: 875-881. DOI: 10.1002/1526-4998(200010)56:10<875::AID-PS220>3.0.CO;2-A  0.104
Hide low-probability matches.